

## **Tomato extract could challenge Aspirin**

Provexis recently announced that it has completed the human trial comparing the effects of Fruitflow, its anti-thrombotic technology made from tomato extract, with aspirin.

Provexis focuses on the discovery, development and licensing of scientifically-proven functional food, medical food and dietary supplement technologies. Results from the trial show that Fruitflow inhibits several pathways involved in platelet aggregation. In contrast, Aspirin, an anti-inflammatory drug, primarily targets only one specific platelet aggregation pathway. The results demonstrate that Fruitflow is effective in preventing platelet aggregation, with no reported side effects. This means Fruitflow could potentially be used as a preventative measure in cardiovascular health. The trial was undertaken by Provexis at the Rowett Institute of Nutrition and Health, part of the University of Aberdeen. The trial compared the effects of Fruitflow and aspirin over a five hour time course. Interactions between Fruitflow and aspirin when consumed together were also studied. 43 healthy subjects completed the trial over a 7 month period and the results are statistically significant.

Fruitflow showed up to 30% reduction from baseline platelet aggregation in each of three different biological pathways, while a single dose of aspirin caused up to 60% reduction in a single pathway, with lesser effects on the other two. The broader antiplatelet effect of Fruitflow reflects the Company's aim to provide a daily dietary supplement with a significant effect on blood flow, but without suppressing platelet aggregation completely.

(Source: Stockopedia.co.uk, March 2010)